Cargando…
HIV/HCV-coinfection: which role can new antiretrovirals such as integrase inhibitors play?
End-stage liver disease has become one of the most frequent causes of death in HIV/HCV-coinfected patients. The role of new antiretrovirals in the progression of liver fibrosis has yet to be defined. However with significant toxicities and drug-to-drug interactions of nucleoside reverse transcriptas...
Autores principales: | Vogel, Martin, Nelson, Mark |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3516823/ https://www.ncbi.nlm.nih.gov/pubmed/19959415 http://dx.doi.org/10.1186/2047-783X-14-S3-36 |
Ejemplares similares
-
Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals
por: Martinez, Valrie, et al.
Publicado: (2012) -
Hepatic steatosis in HIV-HCV coinfected patients receiving
antiretroviral therapy is associated with HCV-related factors but not
antiretrovirals
por: Martinez, Valérie, et al.
Publicado: (2013) -
Integrase inhibitors versus efavirenz combination antiretroviral therapies for TB/HIV coinfection: a meta-analysis of randomized controlled trials
por: Shu, Yuanlu, et al.
Publicado: (2021) -
Incidence of Severe Hepatotoxicity Related to Antiretroviral Therapy in HIV/HCV Coinfected Patients
por: Heil, Emily L., et al.
Publicado: (2010) -
Managing HCV/HIV coinfection
por: Danish, Fazal A., et al.
Publicado: (2009)